Key facts
as of Sep 2026- Myosin Therapeutics’s last known valuation is $30.0M (Feb 2025).
- It has raised $6.9M across 1 recorded rounds; the latest was Seed Round ($3.0M) in Dec 2022.
- Notable investors include National Institutes of Health, Endless Frontier Labs, Florida Opportunity Fund, Mayo Clinic Ventures, Deepwork Capital — 11 tracked in total.
- 1 institutional filer reports fund marks on Myosin Therapeutics across 2 filings.
- Myosin Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Mar 2023 ($3.0M sold to 4 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$1per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Myosin Therapeutics
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Myosin Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 2 fair-value marks on Myosin Therapeutics between May 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Myosin Therapeutics
Operator of a biopharmaceutical company intended to treat significant unmet medical needs. The company focuses on developing novel medications targeting cellular motor proteins and specializes in molecular machines that convert energy into mechanical work inside cells, enabling doctors to treat areas of disease through the development of novel pharmacotherapies.
- Sector
- Healthcare
- HQ
- Jupiter, FL, United States
- Founded
- 2020
- Employees
- 10
- Website
- myosintherapeutics.com/
- Ownership
- Privately Held (backing)